|
|
high content analysis
03-04-08
CELL KINETICS LTD.
(an indirect majority-owned subsidiary of Medis Technologies Ltd.)
CONTACT:
Cell Kinetics Ltd.
Jacob Weiss
Chairman
(212) 935-8484
011-972-8918-8630
FOR IMMEDIATE RELEASE
Cell Kinetics signs distribution agreement with Rikaken Co., Ltd. Japan
April 2, 2008 - New York, N.Y. -- Cell Kinetics Ltd. (OTCBB: CKNTF), announced today that it has signed with Rikaken Co., Ltd. an exclusive distribution agreement for the marketing and distribution of Cell Kinetics’ “CKChip™” in Japan.
“This is a significant moment for Cell Kinetics. This distribution agreement with Rikaken reflects the first step in our commercialization plans to enter into strategic distribution agreements for our CKChip with first class partners in key markets such as Japan, Europe and of course the US. We are proud that a leading Japanese distributor of medical laboratory equipment has decided to market our innovative product to the Japanese market,” said Dr. Asaf Ben-Arye, Cell Kinetics’ President and CEO.
The President of Rikaken Co., Ltd., Mr. Yoshio Morikawa said, “The CKChip is a unique new technology for single cell research, in particular for acquisition of kinetic data, and we believe that the CKChip has various research and, ultimately, clinical applications. This contract with Cell Kinetics Ltd. adds an important dimension to our management strategy, and we are very excited to be able to provide this new product offering to our established customer base, as well as see this as allowing us to expand that base even further. We expect a long-term mutually beneficial collaborative relationship for both companies.”
Cell Kinetics an indirect majority-owned subsidiary of Medis Technologies Ltd. (NASDAQ: MDTL) is developing and will market a series of products, based on its Cell Carrier technology, under the “CKChip™” trade name. The CKChip can accommodate up to 10,000 cells on individual wells for measuring reactions of living cells in a static state over time, using simple imaging methods such as fluorescence microscopy. Cell Kinetics has also invested in an early stage Israeli-based medical device company and intends to continue to source, vet and invest in early stage Israeli-based medical device technologies.
Rikaken Co. is distributor of lab equipment and chemicals operating in the field for over 30 years. The company employees 222 sales and administration staff, responsible for the distribution of general chemicals and reagents, lab disposables, clinical test equipment, lab instruments, and clinical test equipment. Rikaken’s revenues in 2006 were 15 billion Yen and prospects for 2007 were 16.8 billion Yen.
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “expects,” “plans,” “targets,” “believes,” “anticipates,” “estimates,” “predicts,” “potential,” or “continue” or the negative of those words and other comparable words. These forward-looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.
|
14-01-2008
CELL KINETICS LTD.
(an indirect majority-owned subsidiary of Medis Technologies Ltd.)
CONTACT:
Cell Kinetics Ltd.
Jacob Weiss
Chairman
(212) 935-8484
011-972-8918-8630
FOR IMMEDIATE RELEASE
Cell Kinetics Receives Ticker Symbol
February 11, 2008 - New York, N.Y. -- Cell Kinetics Ltd., an indirect majority-owned subsidiary of Medis Technologies Ltd. (NASDAQ: MDTL), announced today that after the successful completion of its Rights Offering, it has received the ticker symbol of CKNTF for the quotation of its ordinary shares in the over-the-counter market on the OTC Bulletin Board maintained by the FINRA.
The Rights Offering subscribers purchased an aggregate of 3,492,788 Cell Kinetics ordinary shares, at the subscription price of $0.30 per share, and subscribers also received four year warrants to purchase additional Cell Kinetics ordinary shares, at an exercise price of $0.60 per share, at the rate of one such warrant for every two ordinary shares purchased in the Rights Offering.
Cell Kinetics is developing and will market a series of products, its Cell Carrier, under the “CKChip™” trade name. The CKChip can accommodate up to 10,000 cells on individual wells for measuring reactions of living cells in a static state for a considerably long period of time using simple imaging methods such as fluorescence microscopy. Cell Kinetics also intends to source, vet and invest in early stage Israeli-based medical device companies.
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risk, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company’s filings with the SEC.
|
high content analysis
14-01-2008
CELL KINETICS LTD.
(an indirect majority-owned subsidiary of Medis Technologies Ltd.)
CONTACT:
CellKinetics Ltd.
Jacob Weiss
Chairman
(212) 935-8484
011-972-8918-8630
FOR IMMEDIATE RELEASE
Cell Kinetics Completes Over-Subscribed Rights Offering
JANUARY 14, 2008 - New York, N.Y. -- Cell Kinetics Ltd., an indirect majority-owned subsidiary of Medis Technologies Ltd. (NASDAQ: MDTL), announced today that the Cell Kinetics’ rights offering (the “Rights Offering”) that expired on January 7, 2008 was over-subscribed and those subscribers who purchased all ordinary shares underlying their basic subscription rights and chose to exercise their over-subscription rights will receive additional shares of Cell Kinetics based on the formula set forth in November 5, 2007 Rights Offering prospectus.
Upon completion of administrative procedures, Cell Kinetics will distribute to Rights Offering subscribers an aggregate of 3,492,788 Cell Kinetics ordinary shares, at the subscription price of $0.30 per share. Rights Offering subscribers will also receive four year warrants to purchase additional Cell Kinetics ordinary shares, at an exercise price of $0.60 per share, at the rate of one such warrant for every two ordinary shares purchased in the Rights Offering.
“We are very pleased with the successful conclusion of the rights offering to Medis Technologies’ shareholders of Cell Kinetics shares and the level of interest as demonstrated by the over-subscription is very gratifying. We look forward in 2008 to Cell Kinetics continuing to develop and commercialize its products,” commented Jacob Weiss, Chairman of Cell Kinetics.
Copies of the prospectus relating to the Rights Offering may be obtained for informational purposes by calling (212) 935-8484. A copy of the prospectus is also available through the SEC’s Internet website, located at http://www.sec.gov.
Cell Kinetics markets Medis’ Cell Carrier, under the “CKChip™” trade name. The Company presented the product at the American Society of Cell Biology meeting that took place in December of 2007. Cell Kinetics also intends to source, vet and invest in early stage Israeli-based medical device companies.
______________________
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities of Cell Kinetics in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risk, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company’s filings with the SEC.
|
14-12-2007
CELL KINETICS LTD.
(an indirect wholly-owned subsidiary of Medis Technologies Ltd.)
CONTACT:
Cell Kinetics Ltd.
Jacob Weiss
Chairman
(212) 935-8484
011-972-8918-8630
FOR IMMEDIATE RELEASE
Cell Kinetics Extends Expiration Date of Rights Offering to January 7, 2008
December 14, 2007 - New York, N.Y. -- Cell Kinetics Ltd., an indirect, wholly-owned subsidiary of Medis Technologies Ltd. (NASDAQ: MDTL), announced today the extension of the expiration date of Cell Kinetics’ rights offering (the “Rights Offering”) to January 7, 2008 to allow for the completion of certain state securities or
“blue sky law” qualifications of the Rights Offering.
Cell Kinetics has distributed to record holders of Medis’ outstanding common stock, at no cost, nontransferable subscription rights to purchase up to an aggregate of 3,505,337 of Cell Kinetics’ ordinary shares, at a subscription price of $0.30 per share. Record holders of Medis’ common stock received one subscription right for every ten shares of Medis’ common stock held by them as of the close of business on the record date, which was November 12, 2007. Medis record holders who purchase Cell Kinetics’ ordinary shares in the Rights Offering will also receive four year warrants to purchase additional Cell Kinetics ordinary shares, at an exercise price of $0.60 per share, at the rate of one such warrant for every two ordinary shares purchased in the Rights Offering. The Rights Offering was originally scheduled to expire at 5:00 p.m., New York City time, on December 17, 2007.
The new expiration date for the Rights Offering is 5:00 p.m., New York City time, on January 7, 2008, unless
extended.
Copies of the prospectus relating to the Rights Offering may be obtained by calling (212) 935-8484. A copy of the prospectus is also available through the SEC’s Internet website, located at http://www.sec.gov.
Cell Kinetics intends to commercialize Medis’ Cell Carrier, which Cell Kinetics intends to market under the “CKChip™” tradename, and related technology. Cell Kinetics also intends to source, vet and invest in early stage Israeli-based medical device companies.
______________________
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of such rights or common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risk, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company’s filings with the SEC.
|
11-12-2007
Cell Kinetics announces that it has been awarded ISO 9001:2000 Certificate, for the designed development assembly and marketing of devices including software used for cell research, testing and analysis.
|
04-12-2007
Cell Kinetics presented its CKChip technology in a scientific seminar at the NIH Bethesda MD on December 4. The title of the lecture given by Prof. Gideon Berke and Dr. Lilach Weisz was: “Introducing the CK Chip: Image-Based Monitoring of Multiple Living Cells Over Time Made Easy”
|
29-11-2007
Come visit Cell Kinetics at the annual meetings of the American Society of Cell Biology in Washington DC December 1-5. We will display our “CKChip” technology in our booth no. 1015.
|
28-11-2007
Cell Kinetics presented its CKChip technology in a scientific seminar at the Department of Microbiology at Boston University Medical Center on November 28. The title of the lecture given by Prof. Gideon Berke and Dr. Lilach Weisz was: “Introducing the CK Chip: Image-Based Monitoring of Multiple Living Cells Over Time Made Easy”
|
21-02-2008
Cell Kinetics presented its CKChip technology in a scientific seminar at the Greiner Bio-One GmbH on February 18. The title of the lecture given by Prof. Gideon Berke and Dr. Lilach Weisz is: "Single Cell Kinetics made easy: A novel device (CK Chip) enables quantitative imaging of numerous non-adherent cells over time"
|
|
|
|
|